GOLGA4 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the GOLGA4 gene has been disrupted in the HT29 human colorectal adenocarcinoma cell line. This product provides a loss-of-function model for studying the role of the cis-Golgi matrix protein GOLGA4 in Golgi architecture, vesicle tethering, and secretory trafficking. As a polyclonal population, it retains the genetic diversity typical of unselected pools, enabling users to observe phenotypic consequences of GOLGA4 disruption without the confounding effects of clonal selection. The knockout model is well-suited for comparative studies alongside wild-type HT29 cells, offering a versatile system for investigating Golgi-dependent cellular processes in a colorectal cancer background.
The HT29 cell line is an adherent epithelial line originally derived from a female patient with colorectal adenocarcinoma. Widely employed as a model for colorectal cancer, HT29 cells exhibit robust proliferation, characteristic epithelial morphology, and well-documented signaling pathways relevant to oncogenesis and drug response. Their use in cancer biology and drug development is extensive, and they serve as a standard platform for investigating mechanisms of tumor cell growth, differentiation, and metastasis. Importantly, HT29 cells retain a functional, polarized Golgi apparatus, making them an ideal host for examining the impact of GOLGA4 ablation on organelle structure and function in a disease-relevant context.
GOLGA4, a member of the golgin family, functions as a tethering factor at the trans-Golgi network (TGN) and is recruited to membranes by the small GTPase ARL1. It interacts with ARF1, GOLGA2 (GM130), GOLGA3, and various motor proteins to coordinate the docking and fusion of transport vesicles, thereby maintaining Golgi ribbon integrity and facilitating anterograde and retrograde trafficking. The mechanistic summary indicates that GOLGA4 acts downstream of ARL1 and ARF1 signaling, contributing to the tethering of COPI vesicles and the assembly of SNARE complexes that drive membrane fusion. Disruption of GOLGA4 expression is predicted to impair Golgi organization and cargo secretion, with potential effects on the localization of TGN-resident proteins and the kinetics of ER-to-Golgi transport.
In the HT29 cell background, disruption of GOLGA4 provides a means to dissect the contribution of Golgi architecture to colorectal cancer cell biology. Secretory pathways are frequently dysregulated in cancer, and Golgi structural proteins can influence the trafficking of growth factor receptors, adhesion molecules, and matrix metalloproteinases that drive tumor progression. Loss of GOLGA4 may alter the secretion of autocrine and paracrine factors, impacting cell proliferation, migration, and invasion. Consequently, this knockout model allows researchers to explore whether Golgi tethering defects modulate oncogenic signaling networks, such as those involving the EGF or Wnt pathways, which rely on proper receptor presentation and ligand release. The system also offers a platform to test whether pharmacological agents targeting trafficking pathways exert differential effects in the absence of GOLGA4.
Typical applications include immunofluorescence microscopy to assess TGN46 distribution, western blotting to confirm GOLGA4 depletion, and VSVG-GFP trafficking assays to monitor cargo transport kinetics. Researchers can employ co-immunoprecipitation to map altered golgin interactions, electron microscopy to visualize Golgi stack morphology, and ELISA-based secretion assays to quantify released proteins. Functional readouts may extend to cell migration and invasion chambers, as well as drug sensitivity testing against trafficking inhibitors or chemotherapeutics. The GOLGA4 Knockout HT29 Polyclonal Cells thus serve as a refined tool for investigating the intersection of cargo trafficking and colorectal cancer pathology. For further information or to inquire about custom models, please contact Ascent Research.
